Cargando…

RIPK1 and RIPK3 are positive prognosticators for cervical cancer patients and C2 ceramide can inhibit tumor cell proliferation in vitro

INTRODUCTION: The enzymes Receptor-interacting serine/threonine-protein kinase 1 (RIPK1) und 3 (RIPK3) as well as the protein Mixed lineage kinase domain like pseudokinase (pMLKL) play a role in the signaling cascade of necroptosis. This is a form of programmed cell death which is caspase-independen...

Descripción completa

Detalles Bibliográficos
Autores principales: Vogelsang, Tilman L. R., Kast, Verena, Bagnjuk, Konstantin, Eubler, Katja, Jeevanandan, Sree Priyanka, Schmoeckel, Elisa, Trebo, Anna, Topalov, Nicole Elisabeth, Mahner, Sven, Mayr, Doris, Mayerhofer, Artur, Jeschke, Udo, Vattai, Aurelia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10183606/
https://www.ncbi.nlm.nih.gov/pubmed/37197430
http://dx.doi.org/10.3389/fonc.2023.1110939
_version_ 1785041989868191744
author Vogelsang, Tilman L. R.
Kast, Verena
Bagnjuk, Konstantin
Eubler, Katja
Jeevanandan, Sree Priyanka
Schmoeckel, Elisa
Trebo, Anna
Topalov, Nicole Elisabeth
Mahner, Sven
Mayr, Doris
Mayerhofer, Artur
Jeschke, Udo
Vattai, Aurelia
author_facet Vogelsang, Tilman L. R.
Kast, Verena
Bagnjuk, Konstantin
Eubler, Katja
Jeevanandan, Sree Priyanka
Schmoeckel, Elisa
Trebo, Anna
Topalov, Nicole Elisabeth
Mahner, Sven
Mayr, Doris
Mayerhofer, Artur
Jeschke, Udo
Vattai, Aurelia
author_sort Vogelsang, Tilman L. R.
collection PubMed
description INTRODUCTION: The enzymes Receptor-interacting serine/threonine-protein kinase 1 (RIPK1) und 3 (RIPK3) as well as the protein Mixed lineage kinase domain like pseudokinase (pMLKL) play a role in the signaling cascade of necroptosis. This is a form of programmed cell death which is caspase-independent. High-risk human papilloma virus infection can inhibit necroptosis. Thereby, a persistent infection and consequently the development of cervical cancer can be triggered. Aim of this study was the analysis of the expression of RIPK1, RIPK3 and pMLKL in cervical cancer tissue and the evaluation of its prognostic value on overall survival, progression-free survival and additional clinical parameters. METHODS: The expression of RIPK1, RIPK3, and pMLKL in cervical cancer tissue microarrays of n = 250 patients was analyzed immunohistochemically. Further, the effect of C2 ceramide on several cervical cancer cell lines (CaSki, HeLa, SiHa) was examined. C2 ceramide is a biologically active short-chain ceramide that induces necroptosis in human luteal granulosa cells. RESULTS: Significantly longer overall survival and progression-free survival rates could be detected in cervical cancer patients expressing nuclear RIPK1 or RIPK3 alone or simultaneously (RIPK1 and RIPK3). Cell viability and proliferation was reduced through C2 ceramide stimulation of cervical cancer cells. Simultaneous stimulation of C2 ceramide and the pan-caspase inhibitor Z-VAD-fmk, or the RIPK1-inhibitor necrostatin-1, partly reversed the negative effect of C2 ceramide on cell viability. This observation could imply that caspase-dependent and -independent forms of cell death, including necroptosis, can occur. AnnexinV-FITC apoptosis staining induced a significant increase in apoptotic cells in CaSki and SiHa cells. The stimulation of CaSki cells with C2 ceramide led to a significant percentual increase in necrotic/intermediate (dying) cells after stimulation with C2 ceramide. In addition, after stimulation with C2 ceramide, CaSki and HeLa cells live cell imaging showed morphological changes which are common for necroptosis. DISCUSSION: In conclusion, RIPK1 and RIPK3 are independent positive predictors for overall survival and progression-free survival in cervical cancer patients. C2 ceramide can reduce cell viability and proliferation in cervical cancer cells by inducing most likely both apoptosis and necroptosis.
format Online
Article
Text
id pubmed-10183606
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-101836062023-05-16 RIPK1 and RIPK3 are positive prognosticators for cervical cancer patients and C2 ceramide can inhibit tumor cell proliferation in vitro Vogelsang, Tilman L. R. Kast, Verena Bagnjuk, Konstantin Eubler, Katja Jeevanandan, Sree Priyanka Schmoeckel, Elisa Trebo, Anna Topalov, Nicole Elisabeth Mahner, Sven Mayr, Doris Mayerhofer, Artur Jeschke, Udo Vattai, Aurelia Front Oncol Oncology INTRODUCTION: The enzymes Receptor-interacting serine/threonine-protein kinase 1 (RIPK1) und 3 (RIPK3) as well as the protein Mixed lineage kinase domain like pseudokinase (pMLKL) play a role in the signaling cascade of necroptosis. This is a form of programmed cell death which is caspase-independent. High-risk human papilloma virus infection can inhibit necroptosis. Thereby, a persistent infection and consequently the development of cervical cancer can be triggered. Aim of this study was the analysis of the expression of RIPK1, RIPK3 and pMLKL in cervical cancer tissue and the evaluation of its prognostic value on overall survival, progression-free survival and additional clinical parameters. METHODS: The expression of RIPK1, RIPK3, and pMLKL in cervical cancer tissue microarrays of n = 250 patients was analyzed immunohistochemically. Further, the effect of C2 ceramide on several cervical cancer cell lines (CaSki, HeLa, SiHa) was examined. C2 ceramide is a biologically active short-chain ceramide that induces necroptosis in human luteal granulosa cells. RESULTS: Significantly longer overall survival and progression-free survival rates could be detected in cervical cancer patients expressing nuclear RIPK1 or RIPK3 alone or simultaneously (RIPK1 and RIPK3). Cell viability and proliferation was reduced through C2 ceramide stimulation of cervical cancer cells. Simultaneous stimulation of C2 ceramide and the pan-caspase inhibitor Z-VAD-fmk, or the RIPK1-inhibitor necrostatin-1, partly reversed the negative effect of C2 ceramide on cell viability. This observation could imply that caspase-dependent and -independent forms of cell death, including necroptosis, can occur. AnnexinV-FITC apoptosis staining induced a significant increase in apoptotic cells in CaSki and SiHa cells. The stimulation of CaSki cells with C2 ceramide led to a significant percentual increase in necrotic/intermediate (dying) cells after stimulation with C2 ceramide. In addition, after stimulation with C2 ceramide, CaSki and HeLa cells live cell imaging showed morphological changes which are common for necroptosis. DISCUSSION: In conclusion, RIPK1 and RIPK3 are independent positive predictors for overall survival and progression-free survival in cervical cancer patients. C2 ceramide can reduce cell viability and proliferation in cervical cancer cells by inducing most likely both apoptosis and necroptosis. Frontiers Media S.A. 2023-05-01 /pmc/articles/PMC10183606/ /pubmed/37197430 http://dx.doi.org/10.3389/fonc.2023.1110939 Text en Copyright © 2023 Vogelsang, Kast, Bagnjuk, Eubler, Jeevanandan, Schmoeckel, Trebo, Topalov, Mahner, Mayr, Mayerhofer, Jeschke and Vattai https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Vogelsang, Tilman L. R.
Kast, Verena
Bagnjuk, Konstantin
Eubler, Katja
Jeevanandan, Sree Priyanka
Schmoeckel, Elisa
Trebo, Anna
Topalov, Nicole Elisabeth
Mahner, Sven
Mayr, Doris
Mayerhofer, Artur
Jeschke, Udo
Vattai, Aurelia
RIPK1 and RIPK3 are positive prognosticators for cervical cancer patients and C2 ceramide can inhibit tumor cell proliferation in vitro
title RIPK1 and RIPK3 are positive prognosticators for cervical cancer patients and C2 ceramide can inhibit tumor cell proliferation in vitro
title_full RIPK1 and RIPK3 are positive prognosticators for cervical cancer patients and C2 ceramide can inhibit tumor cell proliferation in vitro
title_fullStr RIPK1 and RIPK3 are positive prognosticators for cervical cancer patients and C2 ceramide can inhibit tumor cell proliferation in vitro
title_full_unstemmed RIPK1 and RIPK3 are positive prognosticators for cervical cancer patients and C2 ceramide can inhibit tumor cell proliferation in vitro
title_short RIPK1 and RIPK3 are positive prognosticators for cervical cancer patients and C2 ceramide can inhibit tumor cell proliferation in vitro
title_sort ripk1 and ripk3 are positive prognosticators for cervical cancer patients and c2 ceramide can inhibit tumor cell proliferation in vitro
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10183606/
https://www.ncbi.nlm.nih.gov/pubmed/37197430
http://dx.doi.org/10.3389/fonc.2023.1110939
work_keys_str_mv AT vogelsangtilmanlr ripk1andripk3arepositiveprognosticatorsforcervicalcancerpatientsandc2ceramidecaninhibittumorcellproliferationinvitro
AT kastverena ripk1andripk3arepositiveprognosticatorsforcervicalcancerpatientsandc2ceramidecaninhibittumorcellproliferationinvitro
AT bagnjukkonstantin ripk1andripk3arepositiveprognosticatorsforcervicalcancerpatientsandc2ceramidecaninhibittumorcellproliferationinvitro
AT eublerkatja ripk1andripk3arepositiveprognosticatorsforcervicalcancerpatientsandc2ceramidecaninhibittumorcellproliferationinvitro
AT jeevanandansreepriyanka ripk1andripk3arepositiveprognosticatorsforcervicalcancerpatientsandc2ceramidecaninhibittumorcellproliferationinvitro
AT schmoeckelelisa ripk1andripk3arepositiveprognosticatorsforcervicalcancerpatientsandc2ceramidecaninhibittumorcellproliferationinvitro
AT treboanna ripk1andripk3arepositiveprognosticatorsforcervicalcancerpatientsandc2ceramidecaninhibittumorcellproliferationinvitro
AT topalovnicoleelisabeth ripk1andripk3arepositiveprognosticatorsforcervicalcancerpatientsandc2ceramidecaninhibittumorcellproliferationinvitro
AT mahnersven ripk1andripk3arepositiveprognosticatorsforcervicalcancerpatientsandc2ceramidecaninhibittumorcellproliferationinvitro
AT mayrdoris ripk1andripk3arepositiveprognosticatorsforcervicalcancerpatientsandc2ceramidecaninhibittumorcellproliferationinvitro
AT mayerhoferartur ripk1andripk3arepositiveprognosticatorsforcervicalcancerpatientsandc2ceramidecaninhibittumorcellproliferationinvitro
AT jeschkeudo ripk1andripk3arepositiveprognosticatorsforcervicalcancerpatientsandc2ceramidecaninhibittumorcellproliferationinvitro
AT vattaiaurelia ripk1andripk3arepositiveprognosticatorsforcervicalcancerpatientsandc2ceramidecaninhibittumorcellproliferationinvitro